FierceBiotech20h
Insilico's AI-designed med tied to respiratory health improvements in midstage lung disease trial
Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...
pharmaphorum8d
Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3
Boehringer Ingelheim has moved one of its top pipeline ... Boehringer is a well-established presence in the IPF treatment market with Ofev (nintedanib), one of the German drugmaker's top-selling ...
pharmaphorum5d
Boehringer says R&D pipeline is the best in its long history
Boehringer Ingelheim says it is on track to launch 25 ... of its recent CKD approval as well as pulmonary fibrosis therapy Ofev (nintedanib). According to a Reuters report, the company has now ...
precisionmedicineonline22d
Study Identifies Predictive Biomarker of Response to Anti-Fibrotic Therapy in Early Breast Cancer
NEW YORK – Researchers have identified a gene signature that can predict whether early-stage breast cancer patients will respond to neoadjuvant treatment with anti-fibrotic therapies, such as ...
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of ...
With $66 million R&D center, Boehringer Ingelheim fulfills economic development pledge to state
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
FierceBiotech12d
Boehringer Ingelheim drops obesity drug from Gubra partnership
Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...
Zawya12d
Boehringer Ingelheim announces the appointment of new General Manager for Saudi Arabia, Gulf, and East Africa
Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure sustainable patient access to Boehringer Ingelheim’s portfolio of leading ...
FiercePharma12d
Boehringer, Amgen, Novartis sweep corporate reputation rankings among cardiovascular patient groups
A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. | A new survey shows that three Big Pharmas have ...
‘Sick day’ on the clock: CT Biopharma firm expands patient simulations to spark creativity, empathy
Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...
Financial Post29d
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...
dvm36014d
Boehringer Ingelheim announces research and development facility expansion
The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals Boehringer Ingelheim shared earlier this month that it has officially opened the ...